The Role of Pioglitazone in Alzheimer's Disea...

The Role of Pioglitazone in Alzheimer's Disease Treatment

Author Name : Dattatray S. Sane, Rajesh S. Adam, Shriniwas A. Vasi, Arya C. Jatla

DOI: https://doi.org/10.56025/IJARESM.2023.120124981

ABSTRACT Alzheimer's disease (AD) is a complex neurodegenerative condition marked by a build-up of pathological signs, including amyloid-beta plaques, and cognitive impairment. The thiazolidinedione pioglitazone, which is mainly used to treat diabetes, has attracted interest due to its possible therapeutic application in Alzheimer's disease. Through the activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ), these medication exhibits anti-inflammatory and neuroprotective characteristics that provide a variety of approaches to dealing with AD pathogenesis. Preclinical research points to pioglitazone's ability to control amyloid-beta buildup, a critical step in the etiology of AD. Although the results of clinical trials have been inconsistent with regard to cognitive enhancements, the medication's potential influence on several aspects of AD pathogenesis is nevertheless fascinating. However, multiple barriers such as diverse research findings and the need to account for cardiovascular hazards highlight the complexity of its implementation. To clarify mechanisms, determine ideal patient profiles, and prove pioglitazone's long-term safety and efficacy in treating AD, more study is necessary. This abstract shows the changing field of pioglitazone's investigation, from a diabetes drug to a possible treatment option in the complex field of Alzheimer's disease.